270 related articles for article (PubMed ID: 26338207)
1. Cyclometalated Ruthenium(II) Anthraquinone Complexes Exhibit Strong Anticancer Activity in Hypoxic Tumor Cells.
Zeng L; Chen Y; Huang H; Wang J; Zhao D; Ji L; Chao H
Chemistry; 2015 Oct; 21(43):15308-19. PubMed ID: 26338207
[TBL] [Abstract][Full Text] [Related]
2. Ruthenium(II) polypyridyl complexes: cellular uptake, cell image and apoptosis of HeLa cancer cells induced by double targets.
Yu Q; Liu Y; Xu L; Zheng C; Le F; Qin X; Liu Y; Liu J
Eur J Med Chem; 2014 Jul; 82():82-95. PubMed ID: 24878637
[TBL] [Abstract][Full Text] [Related]
3. Mixed-ligand ruthenium polypyridyl complexes as apoptosis inducers in cancer cells, the cellular translocation and the important role of ROS-mediated signaling.
Zhao Z; Luo Z; Wu Q; Zheng W; Feng Y; Chen T
Dalton Trans; 2014 Dec; 43(45):17017-28. PubMed ID: 25087850
[TBL] [Abstract][Full Text] [Related]
4. Hypoxia-Targeting Organometallic Ru(II)-Arene Complexes with Enhanced Anticancer Activity in Hypoxic Cancer Cells.
Zhao J; Li W; Gou S; Li S; Lin S; Wei Q; Xu G
Inorg Chem; 2018 Jul; 57(14):8396-8403. PubMed ID: 29953210
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, characterization and anticancer mechanism studies of fluorinated cyclometalated ruthenium(ii) complexes.
Wen Y; Ouyang C; Li Q; Rees TW; Qiu K; Ji L; Chao H
Dalton Trans; 2020 Jun; 49(21):7044-7052. PubMed ID: 32406463
[TBL] [Abstract][Full Text] [Related]
6. Anti-tumor activity and mechanism of apoptosis of A549 induced by ruthenium complex.
Sun D; Mou Z; Li N; Zhang W; Wang Y; Yang E; Wang W
J Biol Inorg Chem; 2016 Dec; 21(8):945-956. PubMed ID: 27620172
[TBL] [Abstract][Full Text] [Related]
7. Hypoxia-Sensitive Metal β-Ketoiminato Complexes Showing Induced Single-Strand DNA Breaks and Cancer Cell Death by Apoptosis.
Lord RM; Hebden AJ; Pask CM; Henderson IR; Allison SJ; Shepherd SL; Phillips RM; McGowan PC
J Med Chem; 2015 Jun; 58(12):4940-53. PubMed ID: 25906293
[TBL] [Abstract][Full Text] [Related]
8. Imine-N-Heterocyclic Carbenes as Versatile Ligands in Ruthenium(II) p-Cymene Anticancer Complexes: A Structure-Activity Relationship Study.
Yang Y; Guo L; Tian Z; Liu X; Gong Y; Zheng H; Ge X; Liu Z
Chem Asian J; 2018 Oct; 13(19):2923-2933. PubMed ID: 30101417
[TBL] [Abstract][Full Text] [Related]
9. Fluorinated cyclometalated iridium(iii) complexes as mitochondria-targeted theranostic anticancer agents.
Ouyang M; Zeng L; Huang H; Jin C; Liu J; Chen Y; Ji L; Chao H
Dalton Trans; 2017 May; 46(20):6734-6744. PubMed ID: 28488721
[TBL] [Abstract][Full Text] [Related]
10. Ru(II) complexes bearing guanidinium ligands as potent anticancer agents.
Chen WX; Song XD; He SF; Sun J; Chen JX; Wu T; Mao ZW
J Inorg Biochem; 2016 Nov; 164():91-98. PubMed ID: 27666421
[TBL] [Abstract][Full Text] [Related]
11. Protein-binding, cytotoxicity in vitro and cell cycle arrest of ruthenium(II) polypyridyl complexes.
Liu SH; Zhu JW; Xu HH; Wang Y; Liu YM; Liang JB; Zhang GQ; Cao DH; Lin YY; Wu Y; Guo QF
Spectrochim Acta A Mol Biomol Spectrosc; 2016 May; 161():77-82. PubMed ID: 26956530
[TBL] [Abstract][Full Text] [Related]
12. Ruthenium(II) Complexes with 2-Phenylimidazo[4,5-f][1,10]phenanthroline Derivatives that Strongly Combat Cisplatin-Resistant Tumor Cells.
Zeng L; Chen Y; Liu J; Huang H; Guan R; Ji L; Chao H
Sci Rep; 2016 Jan; 6():19449. PubMed ID: 26763798
[TBL] [Abstract][Full Text] [Related]
13. Synthesis, Characterization, and in Vitro Antitumor Activity of Ruthenium(II) Polypyridyl Complexes Tethering EGFR-Inhibiting 4-Anilinoquinazolines.
Du J; Kang Y; Zhao Y; Zheng W; Zhang Y; Lin Y; Wang Z; Wang Y; Luo Q; Wu K; Wang F
Inorg Chem; 2016 May; 55(9):4595-605. PubMed ID: 27093574
[TBL] [Abstract][Full Text] [Related]
14. A hypoxia efficient imidazole-based Ru(II) arene anticancer agent resistant to deactivation by glutathione.
Purkait K; Karmakar S; Bhattacharyya S; Chatterjee S; Dey SK; Mukherjee A
Dalton Trans; 2015 Apr; 44(13):5969-73. PubMed ID: 25742181
[TBL] [Abstract][Full Text] [Related]
15. Novel cyclometalated Ru(II) complexes containing isoquinoline ligands: Synthesis, characterization, cellular uptake and in vitro cytotoxicity.
Chen J; Wang J; Deng Y; Li B; Li C; Lin Y; Yang D; Zhang H; Chen L; Wang T
Eur J Med Chem; 2020 Oct; 203():112562. PubMed ID: 32698112
[TBL] [Abstract][Full Text] [Related]
16. Heterobimetallic Ru(ii)/Fe(ii) complexes as potent anticancer agents against breast cancer cells, inducing apoptosis through multiple targets.
Guedes APM; Mello-Andrade F; Pires WC; de Sousa MAM; da Silva PFF; de Camargo MS; Gemeiner H; Amauri MA; Gomes Cardoso C; de Melo Reis PR; Silveira-Lacerda EP; Batista AA
Metallomics; 2020 Apr; 12(4):547-561. PubMed ID: 32108850
[TBL] [Abstract][Full Text] [Related]
17. Mitochondrial fragmentation is an important cellular event induced by ruthenium(II) polypyridyl complexes in osteosarcoma cells.
Du Y; Fu X; Li H; Chen B; Guo Y; Su G; Zhang H; Ning F; Lin Y; Mei W; Chen T
ChemMedChem; 2014 Apr; 9(4):714-8. PubMed ID: 24403015
[TBL] [Abstract][Full Text] [Related]
18. Serendipitous Synthesis of Five-Coordinated Half-Sandwich Aminoimine Iridium(III) and Ruthenium(II) Complexes and Their Application as Potent Anticancer Agents.
Du Q; Guo L; Ge X; Zhao L; Tian Z; Liu X; Zhang F; Liu Z
Inorg Chem; 2019 May; 58(9):5956-5965. PubMed ID: 30986046
[TBL] [Abstract][Full Text] [Related]
19. Strained ruthenium complexes are potent light-activated anticancer agents.
Howerton BS; Heidary DK; Glazer EC
J Am Chem Soc; 2012 May; 134(20):8324-7. PubMed ID: 22553960
[TBL] [Abstract][Full Text] [Related]
20. Experimental and theoretical investigations of cyclometalated ruthenium(ii) complex containing CCC-pincer and anti-inflammatory drugs as ligands: synthesis, characterization, inhibition of cyclooxygenase and in vitro cytotoxicity activities in various cancer cell lines.
Tabrizi L; Olasunkanmi LO; Fadare OA
Dalton Trans; 2019 Jan; 48(2):728-740. PubMed ID: 30560261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
